Evidence map›Paper›PMID 39494582›Full record

ArticleCancer medicine2024

Evaluation of the Prognostic Value of the Mayo Additive Staging System and Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients.

Yichuan Song, Rui Zhao, Wenxuan Fu, Jing Zhao, Qingtao Wang, Rui Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yichuan SongDepartment of Clinical Laboratory, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Rui ZhaoDepartment of Clinical Laboratory, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Wenxuan FuDepartment of Clinical Laboratory, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Jing ZhaoDepartment of Clinical Laboratory, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Qingtao WangDepartment of Clinical Laboratory, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Rui ZhangDepartment of Clinical Laboratory, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0001-7258-8745

Funding

Beijing Chaoyang Hospital Science and Technology Innovation Fund 22kcjjzd-7Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support ZYLX202137
6 · The paper itself

Abstract

introductionThis study aimed to evaluate the prognostic value of the Mayo additive staging system (MASS) and minimal residual disease (MRD) in newly diagnosed multiple myeloma (NDMM) patients.

methodsA total of 238 NDMM patients were enrolled in Beijing Chaoyang Hospital. Fluorescence in-situ hybridization and next-generation flow cytometry were used to examine cytogenetic abnormalities and MRD, respectively. The patients were classified into three groups to compare the effects on progression-free survival (PFS). Univariate and multivariate analyses were applied to identify the survival-related factors.

resultsFor MASS group, the PFS was significant difference in MASS I, II, and III patients (p = 0.0006); the patients with sustained MRD-negative, non-sustained MRD-negative, sustained MRD-positive, and non-sustained MRD-positive were divided into Groups 1, 2, 3, and 4, respectively. The Group 1 patients had superior PFS than Groups 2 and 3 patients (p < 0.05), but no difference in PFS was observed for Group 2 versus Group 3, Group 2 versus Group 4, and Group 3 versus Group 4 patients. For the MASS and MRD groups, among Groups 2, 3, and 4, MASS I patients had a superior PFS, while III patients showed the opposite result. Strikingly, no difference in PFS for Group 1 patients regardless of the MASS stage was observed. Despite being in MASS II and III, the PFS of Group 1 patients was longer than those with the other three groups. Response to treatment was an independent prognostic factor for MM patients.

conclusionPatients with an accumulation of high-risk factors and MRD-positive have poor outcomes. Sustained MRD-negative may improve high-risk patients' prognoses.

Indexed as

Multiple MyelomaNeoplasm, ResidualNeoplasm StagingAdultAgedAged, 80 and overFemaleFlow CytometryHumansIn Situ Hybridization, FluorescenceMaleMiddle AgedPrognosisProgression-Free SurvivalMayo additive staging systemminimal residual diseasemultiple myelomaprognosisresponse to treatment

Identifiers

PMID39494582
PMCPMC11532867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.